MedTrace Logo

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT03761225 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 714

Last updated 2023-09-29

No results posted yet for this study

Summary

Study of masitinib plus docetaxel as first-line chemotherapy in men with metastatic castration-resistant prostate cancer.

Conditions

  • Metastatic Castrate Resistant Prostate Cancer

Interventions

DRUG

Masitinib

DRUG

Docetaxel

DRUG

Prednisone

DRUG

Placebo

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Dominique Spaeth, MD · Polyclinique d'oncologie de Gentilly, Nancy, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2020-12-15
Completion
2020-12-15
FDA Drug
Yes

Countries

  • Canada
  • France
  • India
  • Italy
  • Malaysia
  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03761225 on ClinicalTrials.gov